Interpace Diagnostics acquires assets of Rosetta Genomics out of bankruptcy
Interpace Diagnostics announced that it has successfully acquired a majority of the equipment of Rosetta Genomics' Philadelphia laboratory through a bankruptcy auction. Interpace acquired, for an undisclosed amount of cash, 64 select lots of laboratory assets, including freezers, refrigerators, PCR machines, advanced slide scanning equipment as well as laboratory supplies and specialty furniture. The laboratory assets will further support the company's CLIA and CAP certified lab expansion in its Pittsburgh, PA and New Haven, CT laboratories. Since the bankruptcy filing of Rosetta Genomics in May, the company has also hired several former key Rosetta employees and select former Rosetta customers have transitioned their accounts to Interpace's thyroid assays. Interpace believes it is uniquely licensed to process thyroid slide biopsies, the primary specimen type for Rosetta's Reveal product.